Roche Holding AG (VTX:ROG) has endured a 21% loss in investments over the past three years. The company, however, confirms its FY25 outlook, maintaining a positive outlook on long-term performance.
Roche has been bolstered by sales increases from key drugs like Phesgo and Vabysmo, up 7% in Q1. Consequently, a Buy rating was conferred by
UBS and
Bernstein. A significant acquisition of U.S biopharma company
Poseida and a $5.3 billion deal with Danish obesity drugmaker,
NovoNordisk, have been completed. The latter resulted in a 4% slide in NovoNordisk stocks, giving Roche an edge. Countering tariff threats, Roche pledged a massive $50 billion for U.S investment over the next five years, aiming to create 12,000 jobs. Despite some setbacks involving Roche's higher dose of
Ocrevus failing to meet objectives in an RMS study, Roche remains confident, with its obese drug candidate from
Zealand likely to net $5.3 billion.
Roche Stocks News Analytics from Mon, 22 Jul 2024 07:00:00 GMT to Fri, 25 Apr 2025 10:44:00 GMT -
Rating 5
- Innovation 1
- Information 6
- Rumor -3
